Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Predictive value of HIV-1 genotypic resistance test interpretation algorithms.

Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW.

J Infect Dis. 2009 Aug 1;200(3):453-63. doi: 10.1086/600073.

2.

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group.; ARCA study group..

Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799.

PMID:
21685536
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.

Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM.

Antivir Ther. 2002 Jun;7(2):123-9.

PMID:
12212924
5.

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.

Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group..

J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19.

PMID:
19620134
6.

Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van Laethem K, Zazzi M, van de Vijver DA.

PLoS One. 2010 Jul 9;5(7):e11505. doi: 10.1371/journal.pone.0011505.

7.

Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.

De Luca A, Vendittelli M, Baldini F, Di Giambenedetto S, Trotta MP, Cingolani A, Bacarelli A, Gori C, Perno CF, Antinori A, Ulivi G.

Antivir Ther. 2004 Aug;9(4):583-93.

PMID:
15456090
8.

An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.

Capdepont S, Aurillac-Lavignolle V, Faure M, Dupon M, Morlat P, Ragnaud JM, Chêne G, Fleury H, Masquelier B; GECSA..

J Clin Virol. 2006 May;36(1):36-42. Epub 2006 Feb 28.

PMID:
16513416
9.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

PMID:
21555822
11.

Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.

Ziermann R, Celis L, Derdelinckx I, Lambert C, Veeck J, Rizzo MG, Vanderborght B, Zissis G, Clumeck N, Fransen K, Vaira D, Hendricks D, Van Laethem K, Vandamme AM, Schmit JC, Knechten H, De Luca A, Louwagie J, Segers P, De Boeck K, Pottel H, De Brauwer A, Hulstaert F.

J Clin Virol. 2004 Dec;31 Suppl 1:S7-15.

PMID:
15567089
12.

Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance.

Maggiolo F, Airoldi M, Callegaro A, Ripamonti D, Gregis G, Quinzan G, Bombana E, Ravasio V, Suter F.

J Int Assoc Physicians AIDS Care (Chic). 2007 Jun;6(2):87-93.

PMID:
17537998
13.

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.

Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA Study Group..

Antivir Ther. 2004 Oct;9(5):787-800.

PMID:
15535417
14.

Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.

Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein D, Swanstrom R, Gulick RM; AIDS Clinical Trials Group Study 359 Protocol Team..

AIDS Res Hum Retroviruses. 2008 May;24(5):685-94. doi: 10.1089/aid.2007.0127.

15.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8. Epub 2007 Jan 4.

PMID:
17208042
16.

Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.

De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF, Antinori A.

J Infect Dis. 2003 Jun 15;187(12):1934-43. Epub 2003 May 22.

PMID:
12792870
17.

Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.

Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group..

Infection. 2009 Jun;37(3):233-43. doi: 10.1007/s15010-008-8065-4. Epub 2009 Jan 23.

PMID:
19169632
18.

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Béthune MP, De Smedt G, Woodfall B, Picchio G.

AIDS. 2010 Feb 20;24(4):503-14. doi: 10.1097/QAD.0b013e32833677ac.

PMID:
20051805
19.

HIV-1 genotypic and phenotypic resistance.

Hanna GJ.

Clin Lab Med. 2002 Sep;22(3):637-49. Review.

PMID:
12244590
20.

[Clinical use of HIV-1 resistance genotyping. Predictive factors of poor virological evolution in salvage treatments].

Riera-Jaume M, Peñaranda-Vera M, Ribas-Blanco MA, Murillas-Angoiti J, Campins A, Salas-Aparicio A, Leyes-García M, Pareja-Bezares A, Pérez JL, Villalonga-Pieras C.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):225-31. Spanish.

PMID:
16725081

Supplemental Content

Support Center